Radius Health
Radius Health is a commercial biopharmaceutical company specializing in bone health therapeutics, primarily offering TYMLOS (abaloparatide) and BINOSTO for osteoporosis treatment. The company serves postmenopausal women and men at high fracture risk through direct US sales and international licensing partnerships.
- Company typePrivate
- Founded2013
- HeadquartersCambridge, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Radius Health does
Radius Health is a commercial biopharmaceutical company specializing in bone health therapeutics, with a focus on osteoporosis treatment. Its core product, TYMLOS (abaloparatide), is a novel parathyroid hormone related peptide (PTHrP(1-34)) analog and the first FDA-approved PTHrP analog for osteoporosis, delivered as an 80-microgram daily subcutaneous injection via a single-patient multi-use prefilled pen over a 30-day period. The portfolio also includes BINOSTO (alendronate sodium effervescent tablet), a once-weekly oral osteoporosis therapy licensed from EffRx Pharmaceuticals, which addresses patients who have difficulty swallowing pills. The company serves postmenopausal women and men with osteoporosis at high risk for fracture, with clinical evidence including an 86% relative risk reduction in new vertebral fractures versus placebo in the ACTIVE trial.
The company's underlying technology is differentiated at the molecular level: abaloparatide selectively activates the PTH1 receptor as a bone-forming (anabolic) agent, distinct from teriparatide (PTH 1-34), with real-world evidence showing superior hip fracture reduction (1.1% vs 1.4%, HR 0.83). Five TYMLOS patents, co-held with Ipsen Pharma S.A.S., were upheld in 2025 litigation with the latest expiring April 30, 2038, providing long-term exclusivity.
Radius operates a hybrid commercial model. In the US, it sells directly through authorized distributor networks and specialty pharmacy channels (Medvantx), targeting specialist physicians treating osteoporosis, while supplementing access through the Radius Assist patient assistance program. Internationally, the company pursues a licensing model, granting commercialization rights to Theramex (Europe, Mexico, Canada, South Africa, Israel, Russia, Australia, Brazil), Pharmanovia (Asia Pacific), and Teijin Pharma (Japan), generating upfront, milestone, and tiered royalty revenue. Additional royalty and milestone streams come from the 2020 elacestrant (ORSERDU) licensing to Menarini Group, partially monetized via a $130M sale to DRI Healthcare. Originally a NASDAQ-listed company (RDUS), Radius was taken private in August 2022 by Gurnet Point Capital and Patient Square Capital, with B-FLEXION Life Sciences consolidating full ownership in January 2026. In March 2026, Radius completed its merger with Paratek Pharmaceuticals, integrating TYMLOS, BINOSTO, NUZYRA, and XHANCE into a diversified specialty pharmaceutical platform projected to generate nearly $1 billion in 2026 revenue.
Radius Health firmographics
Firmographics- Name
- Radius Health
- Legal name
- Radius Health, Inc.
- Website
- https://radiuspharm.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Radius Health is a commercial biopharmaceutical company specializing in bone health therapeutics, primarily offering TYMLOS (abaloparatide) and BINOSTO for osteoporosis treatment. The company serves postmenopausal women and men at high fracture risk through direct US sales and international licensing partnerships.
- Ownership category
- akta.pro rank
Where Radius Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Radius Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Direct sales of TYMLOS (abaloparatide injection) and BINOSTO (alendronate sodium) in the US market for osteoporosis treatment.
- Licensing Royalties and Milestones: Royalty streams and milestone payments from licensing agreements with Menarini Group for elacestrant (ORSERDU), Theramex for ELADYNOS in Europe and other territories, Pharmanovia for Asia Pacific, and Teijin for Japan. DRI Healthcare acquired a portion of elacestrant royalties for $130M upfront plus $10M.
- Merger Revenue Impact: Following completion of merger with Paratek Pharmaceuticals in March 2026, the combined company is expected to generate nearly $1 billion in annual revenue in 2026, spanning seven therapeutic areas.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Radius Assist Patient Assistance Program - No cost medication for eligible patients |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Radius Health product offering
Product offeringCore offering
Radius Health is a commercial biopharmaceutical company that develops, manufactures, and markets drug therapies for osteoporosis and related bone health conditions. Its core products are TYMLOS (abaloparatide), a parathyroid hormone-related peptide analog delivered via prefilled pen for high-risk osteoporosis patients, and BINOSTO (alendronate sodium), an effervescent once-weekly oral tablet for osteoporosis treatment. The company also operates the Radius Assist patient assistance program to support patient access.
Product overview
Radius Health is a commercial biopharma company specializing in bone health therapeutics. The company's product portfolio centers on TYMLOS® (abaloparatide injection), a parathyroid hormone related peptide analog for osteoporosis treatment, which received initial FDA approval in 2017 for postmenopausal women and was expanded in 2022 to include men. BINOSTO® (alendronate sodium effervescent tablet) was added in 2023 as an exclusive licensing arrangement, providing a complementary once-weekly oral treatment option for osteoporosis patients. The portfolio is complemented by Radius Assist, a patient assistance program supporting access to TYMLOS® for eligible patients. In March 2026, Radius Health completed a merger with Paratek Pharmaceuticals, integrating TYMLOS® alongside Paratek's NUZYRA® and XHANCE® products into a diversified specialty pharmaceutical platform generating nearly $1 billion in projected 2026 revenue.
Differentiator
Problem solved
Functional benefit
Brands
- Radius Assist: Patient assistance program providing TYMLOS (abaloparatide) injection therapy at no cost to qualified patients in need
Products and services
- TYMLOS (abaloparatide injection) TYMLOS is an abaloparatide injection, a parathyroid hormone related peptide (PTHrP) analog approved by the FDA for treating postmenopausal women and men with osteoporosis at high risk for fracture. Administered as an 80 microgram subcutaneous injection once daily via a single-patient multi-use prefilled pen over a 30-day period.
- BINOSTO (alendronate sodium) BINOSTO is an alendronate sodium effervescent tablet for oral solution, indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. Provides a once-weekly treatment option particularly for patients who may have difficulty swallowing pills.
- ELADYNOS (abaloparatide) ELADYNOS is the European brand name for abaloparatide, commercialized by Theramex under licensing agreement in the European Economic Area, United Kingdom, Australia, Brazil, Mexico, Canada, Israel, South Africa, and Russia.
Quantifiable outcome
- 86% relative risk reduction in new vertebral fractures vs placebo
- +3 more outcomes
Companies that use Radius Health
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Radius Health technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Radius Health partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Paratek PharmaceuticalscoreMerger combination completed March 2026, creating diversified specialty pharmaceutical company expected to generate nearly $1 billion revenue in 2026. TYMLOS added to Paratek's portfolio alongside NUZYRA and XHANCE. Combined company spans infectious disease, podiatry, otolaryngology, allergy, rheumatology, endocrinology, and gynecology.
- PharmanoviamajorLicensing agreement for exclusive commercialization rights to abaloparatide in China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and Philippines. Radius eligible for upfront payment, regulatory and commercial milestones, plus tiered royalties on net sales. Announced January 2, 2025.
- TheramexmajorExpanded licensing agreement granting exclusive commercialization rights for ELADYNOS (abaloparatide) in Mexico, Canada, Israel, South Africa, and Russia. Theramex also commercializes ELADYNOS in EEA, UK, Australia, and Brazil. European approval December 2022, Australian approval November 2024. Radius receives upfront, milestone payments, and tiered royalties.
- EffRx Pharmaceuticals, S.A.majorExclusive licensing and distribution agreement for U.S. rights to BINOSTO (alendronate sodium effervescent tablet) for osteoporosis. EffRx supplies product to Radius. Expands Radius bone health portfolio with second osteoporosis treatment product.
Scale indicators5 records
Recent moves2 records
Radius Health competitors and assessment
Company assessmentDirect peers
- Amgen: Amgen markets Prolia (denosumab) and co-markets Evenity (romosozumab) with UCB, both leading bone-forming/resorption osteoporosis therapies. Amgen is a direct competitor to Radius in the high-risk osteoporosis space and shares the specialist physician channel that Radius targets.
- Eli Lilly: Eli Lilly markets Forteo (teriparatide), the legacy parathyroid hormone analog and TYMLOS's principal head-to-head competitor. Real-world evidence directly compares abaloparatide to teriparatide, making Lilly a directly comparable peer in the anabolic osteoporosis category.
- UCB: UCB co-develops and co-markets Evenity (romosozumab) with Amgen, a sclerostin antibody for postmenopausal osteoporosis. UCB is a direct competitor in the bone-forming osteoporosis space that Radius targets with TYMLOS.
- Theramex: Theramex is Radius's exclusive commercialization partner for ELADYNOS (abaloparatide) across Europe, UK, Australia, Brazil, Mexico, Canada, Israel, South Africa, and Russia. Theramex operates a women's health specialty pharma platform that is directly comparable to Radius's bone-health franchise.
- Paratek Pharmaceuticals: Paratek is the merger partner that combined with Radius Health in March 2026 to form the current combined specialty pharma platform. Paratek's portfolio (NUZYRA, XHANCE) overlaps with Radius's commercial-stage specialty pharma business model and shares therapeutic-area adjacency.
Broad incumbents
- Menarini Group: Menarini holds global development and commercialization rights to Radius's elacestrant (ORSERDU) and operates as a broad specialty pharma incumbent across multiple therapeutic areas including oncology and women's health, directly comparable to Radius's commercialization model.
- Currax Pharmaceuticals: Currax is a privately held specialty pharma company that has overlapping executive talent (Radius's current SVP/General Counsel joined from Currax). It operates as a broader specialty pharma player in adjacent therapeutic areas, comparable as a similarly sized specialty pharma platform.
- BioDelivery Sciences International: BioDelivery Sciences is a specialty pharma with overlapping leadership background (Al Medwar previously served as EVP). It is comparable as a similarly structured specialty pharmaceutical commercialization platform with branded prescription products.
- Recordati Rare Diseases: Recordati Rare Diseases is a specialty pharma company where Radius's SVP Medical Operations previously served as VP of Medical Affairs. It is a comparable specialty pharma platform operating in rare and specialty therapeutic areas with similar commercial infrastructure.
Regional players
- Teijin Pharma: Teijin Pharma holds Japan commercialization rights for ELADYNOS (abaloparatide). As a regional specialty pharma partner commercializing the same asset in Japan, Teijin is directly comparable as a regional peer operating in the same therapeutic category.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights7 records
Customer concentration
Radius Health social profiles
Digital presenceRadius Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Radius Health leadership team
Management profileNumber of profiles
Profiles8 records
Radius Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
Radius Health funding detail
Funding detailFunding overview
Funding rounds9 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Radius Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Radius Health
What does Radius Health do?
Radius Health is a commercial biopharmaceutical company that develops, manufactures, and markets drug therapies for osteoporosis and related bone health conditions. Its core products are TYMLOS (abaloparatide), a parathyroid hormone-related peptide analog delivered via prefilled pen for high-risk osteoporosis patients, and BINOSTO (alendronate sodium), an effervescent once-weekly oral tablet for osteoporosis treatment. The company also operates the Radius Assist patient assistance program to support patient access.
Is Radius Health a public or private company?
Radius Health is a private company. It is classified as private equity controlled and is currently acquired.
When was Radius Health founded?
Radius Health was founded in 2013. It employs 251 to 500 people.
Where is Radius Health based?
Radius Health is headquartered in Cambridge, United States, in the North America region.
How does Radius Health make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties and Milestones and merger Revenue Impact.
Who are Radius Health's main competitors?
Direct peers on record are Amgen, Eli Lilly, UCB, Theramex and Paratek Pharmaceuticals. Broad incumbents are Menarini Group, Currax Pharmaceuticals, BioDelivery Sciences International and Recordati Rare Diseases. Teijin Pharma is listed as a regional player.
Does Radius Health have an API?
No public API is recorded for Radius Health.